Progesterone receptor isoforms PRA and PRB differentially contribute to breast cancer cell migration through interaction with focal adhesion kinase complexes

Molecular Biology of the Cell

Volumn 24, Issue 9, 2013, Pages 1363-1374

  Bellance, Catherine ^a,b   Khan, Junaid A ^a,b,c   Meduri, Geri ^a,b,d   Guiochon Mantel, Anne ^a,b,d   Lombès, Marc ^a,b,e   Loosfelt, Hugues ^a,b  

^a Institut National de la Santé et de la Recherche   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c UNIVERSITY OF AGRICULTURE   (Pakistan)

^d Service de Génétique Moléculaire   (France)

^e BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; FOCAL ADHESION KINASE; GESTAGEN; MIFEPRISTONE; PROGESTERONE RECEPTOR A; PROGESTERONE RECEPTOR B; PROMEGESTONE; TYROSINE; UROKINASE;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL ADHESION; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR INVASION;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; FOCAL ADHESION KINASE 1; FOCAL ADHESIONS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN ISOFORMS; RECEPTORS, PROGESTERONE; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; TRANSCRIPTION, GENETIC; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84877111621     PISSN: 10591524     EISSN: 19394586     Source Type: Journal    
DOI: 10.1091/mbc.E12-11-0807     Document Type: Article

References (85)

1. Amazit L, Roseau A, Khan JA, Chauchereau A, Tyagi RK, Loosfelt H, Leclerc P, Lombes M, Guiochon-Mantel A (2011). Ligand-dependent degradation of SRC-1 is pivotal for progesterone receptor transcriptional activity. Mol Endocrinol 25, 394-408.
2. Bagheri-Yarmand R, Talukder AH, Wang RA, Vadlamudi RK, Kumar R (2004). Metastasis-associated protein 1 deregulation causes inappropriate mammary gland development and tumorigenesis. Development 131, 3469-3479.
3. Ballare C, Uhrig M, Bechtold T, Sancho E, Di Domenico M, Migliaccio A, Auricchio F, Beato M (2003). Two domains of the progesterone receptor interact with the estrogen receptor and are required for progesterone activation of the c-Src/Erk pathway in mammalian cells. Mol Cell Biol 23, 1994-2008.
4. Bernard-Trifilo JA, Lim ST, Hou S, Schlaepfer DD, Ilic D (2006). Analyzing FAK and Pyk2 in early integrin signaling events. Curr Protoc Cell Biol Chapter 14, Unit 14.17.
5. Biermann JC, Holzscheiter L, Kotzsch M, Luther T, Kiechle-Bahat M, Sweep FC, Span PN, Schmitt M, Magdolen V (2008). Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA. Int J Mol Med 21, 251-259.
6. Bogina G, Bortesi L, Marconi M, Venturini M, Lunardi G, Coati F, Massocco A, Manfrin E, Pegoraro C, Zamboni G (2011). Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor loss. Virchows Arch 459, 1-10.
7. Boonyaratanakornkit V, Bi Y, Rudd M, Edwards DP (2008). The role and mechanism of progesterone receptor activation of extra-nuclear signaling pathways in regulating gene transcription and cell cycle progression. Steroids 73, 922-928.
8. Boonyaratanakornkit V, McGowan E, Sherman L, Mancini MA, Cheskis BJ, Edwards DP (2007). The role of extranuclear signaling actions of progesterone receptor in mediating progesterone regulation of gene expression and the cell cycle. Mol Endocrinol 21, 359-375.
9. Boonyaratanakornkit V, Scott M P, Ribon V, Sherman L, Anderson SM, Maller JL, Miller WT, Edwards DP (2001). Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. Mol Cell 8, 269-280.
10. Busso N, Masur SK, Lazega D, Waxman S, Ossowski L (1994). Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells. J Cell Biol 126, 259-270.
11. Carnevale RP et al. (2007). Progestin effects on breast cancer cell proliferation, proteases activation, and in vivo development of metastatic phenotype all depend on progesterone receptor capacity to activate cytoplasmic signaling pathways. Mol Endocrinol 21, 1335-1358.
12. Chapman HA (1997). Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol 9, 714-724.
13. Chazaud B, Ricoux R, Christov C, Plonquet A, Gherardi RK, Barlovatz-Meimon G (2002). Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations. Am J Pathol 160, 237-246.
14. Chen JY et al. (2011). A novel sialyltransferase inhibitor suppresses FAK/paxillin signaling and cancer angiogenesis and metastasis pathways. Cancer Res 71, 473-483.
15. Chiang AC, Massague J (2008). Molecular basis of metastasis. N Engl J Med 359, 2814-2823.
16. Chlebowski RT et al. (2010). Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. J Am Med Assoc 304, 1684-1692.
17. Chlebowski RT et al. (2003). Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. J Am Med Assoc 289, 3243-3253.
18. Coene ED, Gadelha C, White N, Malhas A, Thomas B, Shaw M, Vaux DJ (2011). A novel role for BRCA1 in regulating breast cancer cell spreading and motility. J Cell Biol 192, 497-512.
19. Croucher DR, Saunders DN, Stillfried GE, Ranson M (2007). A structural basis for differential cell signalling by PAI-1 and PAI-2 in breast cancer cells. Biochem J 408, 203-210.
20. Czekay RP, Loskutoff DJ (2004). Unexpected role of plasminogen activator inhibitor 1 in cell adhesion and detachment. Exp Biol Med (Maywood) 229, 1090-1096.
21. Dennis A P, Lonard DM, Nawaz Z, O'Malley BW (2005). Inhibition of the 26S proteasome blocks progesterone receptor-dependent transcription through failed recruitment of RNA polymerase II. J Steroid Biochem Mol Biol 94, 337-346.
22. Deramaudt TB, Dujardin D, Hamadi A, Noulet F, Kolli K, De Mey J, Takeda K, Ronde P (2011). FAK phosphorylation at Tyr-925 regulates cross-talk between focal adhesion turnover and cell protrusion. Mol Biol Cell 22, 964-975.
23. Fabre-Guillevin E et al. (2008). PAI-1 and functional blockade of SNAI1 in breast cancer cell migration. Breast Cancer Res 10, R100.
24. Fu XD, Flamini M, Sanchez AM, Goglia L, Giretti MS, Genazzani AR, Simoncini T (2008a). Progestogens regulate endothelial actin cytoskel-eton and cell movement via the actin-binding protein moesin. Mol Hum Reprod 14, 225-234.
25. Fu XD, Giretti MS, Baldacci C, Garibaldi S, Flamini M, Sanchez AM, Gadducci A, Genazzani AR, Simoncini T (2008b). Extra-nuclear signaling of progesterone receptor to breast cancer cell movement and invasion through the actin cytoskeleton. PLoS One 3, e2790.
26. Fu XD, Goglia L, Sanchez AM, Flamini M, Giretti MS, Tosi V, Genazzani AR, Simoncini T (2010). Progesterone receptor enhances breast cancer cell motility and invasion via extranuclear activation of focal adhesion kinase. Endocr Relat Cancer 17, 431-443.
27. Golubovskaya VM, Finch R, Cance WG (2005). Direct interaction of the N-terminal domain of focal adhesion kinase with the N-terminal transac-tivation domain of p53. J Biol Chem 280, 25008-25021.
28. Graham JD, Yager ML, Hill HD, Byth K, O'Neill GM, Clarke CL (2005). Altered progesterone receptor isoform expression remodels progestin responsiveness of breast cancer cells. Mol Endocrinol 19, 2713-2735.
29. Graham JD, Yeates C, Balleine RL, Harvey SS, Milliken JS, Bilous AM, Clarke CL (1995). Characterization of progesterone receptor A and B expression in human breast cancer. Cancer Res 55, 5063-5068.
30. Guiochon-Mantel A, Delabre K, Lescop P, Milgrom E (1994). Nuclear localization signals also mediate the outward movement of proteins from the nucleus. Proc Natl Acad Sci USA 91, 7179-7183.
31. Guiochon-Mantel A, Lescop P, Christin-Maitre S, Loosfelt H, Perrot-Applanat M, Milgrom E (1991). Nucleocytoplasmic shuttling of the progesterone receptor. EMBO J 10, 3851-3859.
32. Hamadi A, Bouali M, Dontenwill M, Stoeckel H, Takeda K, Ronde P (2005). Regulation of focal adhesion dynamics and disassembly by phosphorylation of FAK at tyrosine 397. J Cell Sci 118, 4415-4425.
33. Hammes SR, Levin ER (2007). Extranuclear steroid receptors: nature and actions. Endocr Rev 28, 726-741.
34. Harbeck N, Kates RE, Schmitt M, Gauger K, Kiechle M, Janicke F, Thomassen C, Look M P, Foekens JA (2004). Urokinase-type plasmino-gen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin Breast Cancer 5, 348-352.
35. Hiscox S, Barnfather P, Hayes E, Bramble P, Christensen J, Nicholson RI, Barrett-Lee P (2010). Inhibition of focal adhesion kinase suppresses the adverse phenotype of endocrine-resistant breast cancer cells and improves endocrine response in endocrine-sensitive cells. Breast Cancer Res Treat 125, 659-669.
36. Ilic D, Furuta Y, Kanazawa S, Takeda N, Sobue K, Nakatsuji N, Nomura S, Fujimoto J, Okada M, Yamamoto T (1995). Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature 377, 539-544.
37. Jacobsen BM, Schittone SA, Richer JK, Horwitz KB (2005). Progesterone-independent effects of human progesterone receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene regulation and tumor biology. Mol Endocrinol 19, 574-587.
38. Janicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, Sweep CG, Selbmann HK, Graeff H, Schmitt M (2001). Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasmino-gen activator inhibitor type 1. J Natl Cancer Inst 93, 913-920.
39. Jo M, Thomas KS, Marozkina N, Amin TJ, Silva CM, Parsons SJ, Gonias SL (2005). Dynamic assembly of the urokinase-type plasminogen activator signaling receptor complex determines the mitogenic activity of urokinase-type plasminogen activator. J Biol Chem 280, 17449-17457.
40. Kato S et al. (2005). Progesterone increases tissue factor gene expression, procoagulant activity, and invasion in the breast cancer cell line ZR-75-1. J Clin Endocrinol Metab 90, 1181-1188.
41. Khan JA, Amazit L, Bellance C, Guiochon-Mantel A, Lombes M, Loosfelt H (2011). p38 and p42/44 MAPKs differentially regulate progesterone receptor A and B isoform stabilization. Mol Endocrinol 25, 1710-1724.
42. Khan JA, Bellance C, Guiochon-Mantel A, Lombes M, Loosfelt H (2012). Differential regulation of breast cancer-associated genes by progesterone receptor isoforms PRA and PRB in a new bi-inducible breast cancer cell line. PLoS One 7, e45993.
43. Labriola L, Salatino M, Proietti CJ, Pecci A, Coso OA, Kornblihtt AR, Charreau EH, Elizalde PV (2003). Heregulin induces transcriptional activation of the progesterone receptor by a mechanism that requires functional ErbB-2 and mitogen-activated protein kinase activation in breast cancer cells. Mol Cell Biol 23, 1095-1111.
44. Lange CA, Shen T, Horwitz KB (2000). Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. Proc Natl Acad Sci USA 97, 1032-1037.
45. Lauffenburger DA, Horwitz AF (1996). Cell migration: a physically integrated molecular process. Cell 84, 359-369.
46. Le Romancer M, Treilleux I, Leconte N, Robin-Lespinasse Y, Sentis S, Bouchekioua-Bouzaghou K, Goddard S, Gobert-Gosse S, Corbo L (2008). Regulation of estrogen rapid signaling through arginine methylation by PRMT1. Mol Cell 31, 212-221.
47. Leissner P, Verjat T, Bachelot T, Paye M, Krause A, Puisieux A, Mougin B (2006). Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node - and hormone receptor-positive breast cancer. BMC Cancer 6, 216.
48. Leo JC, Wang SM, Guo CH, Aw SE, Zhao Y, Li JM, Hui KM, Lin VC (2005). Gene regulation profile reveals consistent anticancer properties of progesterone in hormone-independent breast cancer cells transfected with progesterone receptor. Int J Cancer 117, 561-568.
49. Lim ST, Chen XL, Lim Y, Hanson DA, Vo TT, Howerton K, Larocque N, Fisher SJ, Schlaepfer DD, Ilic D (2008). Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation. Mol Cell 29, 9-22.
50. Lin VC, Eng AS, Hen NE, Ng EH, Chowdhury SH (2001). Effect of progesterone on the invasive properties and tumor growth of progesterone receptor-transfected breast cancer cells MDA-MB-231. Clin Cancer Res 7, 2880-2886.
51. Lin VC, Ng EH, Aw SE, Tan MG, Bay BH (2000). Progesterone induces focal adhesion in breast cancer cells MDA-MB-231 transfected with progesterone receptor complementary DNA. Mol Endocrinol 14, 348-358.
52. Long W, Yi P, Amazit L, LaMarca HL, Ashcroft F, Kumar R, Mancini MA, Tsai SY, Tsai MJ, O'Malley BW (2010). SRC-3Delta4 mediates the interaction of EGFR with FAK to promote cell migration. Mol Cell 37, 321-332.
53. Lorenzo F, Jolivet A, Loosfelt H, Thuvu Hai M, Brailly S, Perrot-Applanat M, Milgrom E (1988). A rapid method of epitope mapping. Application to the study of immunogenic domains and to the characterization of various forms of rabbit progesterone receptor. Eur J Biochem 176, 53-60.
54. Luo M, Guan JL (2010). Focal adhesion kinase: a prominent determinant in breast cancer initiation, progression and metastasis. Cancer Lett 289, 127-139.
55. Ma H, Hong H, Huang SM, Irvine RA, Webb P, Kushner PJ, Coetzee GA, Stallcup MR (1999). Multiple signal input and output domains of the 160-kilodalton nuclear receptor coactivator proteins. Mol Cell Biol 19, 6164-6173.
56. Marbaix E, Donnez J, Courtoy PJ, Eeckhout Y (1992). Progesterone regulates the activity of collagenase and related gelatinases A and B in human endometrial explants. Proc Natl Acad Sci USA 89, 11789-11793.
57. May CD, Sphyris N, Evans KW, Werden SJ, Guo W, Mani SA (2011). Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression. Breast Cancer Res 13, 202.
58. McGowan EM, Clarke CL (1999). Effect of overexpression of progesterone receptor A on endogenous progestin-sensitive endpoints in breast cancer cells. Mol Endocrinol 13, 1657-1671.
59. McMahon GA, Petitclerc E, Stefansson S, Smith E, Wong MK, Westrick RJ, Ginsburg D, Brooks PC, Lawrence DA (2001). Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem 276, 33964-33968.
60. Michael KE, Dumbauld DW, Burns KL, Hanks SK, Garcia AJ (2009). Focal adhesion kinase modulates cell adhesion strengthening via integrin activation. Mol Biol Cell 20, 2508-2519.
61. Migliaccio A, Piccolo D, Castoria G, Di Domenico M, Bilancio A, Lombardi M, Gong W, Beato M, Auricchio F (1998). Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J 17, 2008-2018.
62. Mitra SK, Lim ST, Chi A, Schlaepfer DD (2006). Intrinsic focal adhesion kinase activity controls orthotopic breast carcinoma metastasis via the regulation of urokinase plasminogen activator expression in a syngeneic tumor model. Oncogene 25, 4429-4440.
63. Mitra SK, Schlaepfer DD (2006). Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol 18, 516-523.
64. Mote PA, Bartow S, Tran N, Clarke CL (2002). Loss of co-ordinate expression of progesterone receptors A and B is an early event in breast carcino-genesis. Breast Cancer Res Treat 72, 163-172.
65. Olson D, Pollanen J, Hoyer-Hansen G, Ronne E, Sakaguchi K, Wun TC, Appella E, Dano K, Blasi F (1992). Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor. J Biol Chem 267, 9129-9133.
66. Poole AJ, Li Y, Kim Y, Lin SC, Lee WH, Lee EY (2006). Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 314, 1467-1470.
67. Proietti C et al. (2005). Progestins induce transcriptional activation of signal transducer and activator of transcription 3 (Stat3) via a Jak - and Src-dependent mechanism in breast cancer cells. Mol Cell Biol 25, 4826-4840.
68. Providence KM, Higgins PJ (2004). PAI-1 expression is required for epithelial cell migration in two distinct phases of in vitro wound repair. J Cell Physiol 200, 297-308.
69. Rosenthal DT, Iyer H, Escudero S, Bao L, Wu Z, Ventura AC, Kleer CG, Arruda EM, Garikipati K, Merajver SD (2011). p38gamma promotes breast cancer cell motility and metastasis through regulation of RhoC GTPase, cytoskeletal architecture, and a novel leading edge behavior. Cancer Res 71, 6338-6349.
70. Rossouw JE et al. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 288, 321-333.
71. Sakakibara T, Hibi K, Kodera Y, Ito K, Akiyama S, Nakao A (2004). Plasmi-nogen activator inhibitor-1 as a potential marker for the malignancy of esophageal squamous cell carcinoma. Clin Cancer Res 10, 1375-1378.
72. Schaller MD (2010). Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions. J Cell Sci 123, 1007-1013.
73. Schneider J, Lucas R, Sanchez J, Tejerina A, Ruibal A (2000). Cellular accumulation of uPA-PAI-1 [correction of UPA-PAI-1] and uPA-PAI-2 [correction of UPA-PAI-2] complexes in early (pT1) breast cancer: a new link in the uPA-UPAr-PAI chain. In Vivo 14, 507-511.
74. Smith HW, Marshall CJ (2010). Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 11, 23-36.
75. Sood AK, Coffin JE, Schneider GB, Fletcher MS, DeYoung BR, Gruman LM, Gershenson DM, Schaller MD, Hendrix MJ (2004). Biological signifi-cance of focal adhesion kinase in ovarian cancer: role in migration and invasion. Am J Pathol 165, 1087-1095.
76. Stahl A, Mueller BM (1994). Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res 54, 3066-3071.
77. Tang H, Kerins DM, Hao Q, Inagami T, Vaughan DE (1998). The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells. J Biol Chem 273, 18268-18272.
78. Tyagi RK, Amazit L, Lescop P, Milgrom E, Guiochon-Mantel A (1998). Mechanisms of progesterone receptor export from nuclei: role of nuclear localization signal, nuclear export signal, and ran guanosine triphosphate. Mol Endocrinol 12, 1684-1695.
79. Vincent AJ, Zhang J, Ostor A, Rogers PA, Affandi B, Kovacs G, Salamonsen LA (2002). Decreased tissue inhibitor of metalloproteinase in the endometrium of women using depot medroxyprogesterone acetate: a role for altered endometrial matrix metalloproteinase/tissue inhibitor of metalloproteinase balance in the pathogenesis of abnormal uterine bleeding. Hum Reprod 17, 1189-1198.
80. Waltz DA, Natkin LR, Fujita RM, Wei Y, Chapman HA (1997). Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest 100, 58-67.
81. Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV, Chapman HA (1996). Regulation of integrin function by the urokinase receptor. Science 273, 1551-1555.
82. Wei Y, Tang CH, Kim Y, Robillard L, Zhang F, Kugler MC, Chapman HA (2007). Urokinase receptors are required for alpha 5 beta 1 integrin-mediated signaling in tumor cells. J Biol Chem 282, 3929-3939.
83. Weigelt B, Peterse JL, van't Veer LJ (2005). Breast cancer metastasis: markers and models. Nat Rev Cancer 5, 591-602.
84. Wilkins-Port CE, Higgins CE, Freytag J, Higgins SP, Carlson JA, Higgins PJ (2007). PAI-1 is a critical upstream regulator of the TGF-beta1/EGF-induced invasive phenotype in mutant p53 human cutaneous squamous cell carcinoma. J Biomed Biotechnol 85208.
85. Zheng S, Huang J, Zhou K, Xiang Q, Zhang Y, Tan Z, Simoncini T, Fu X, Wang T (2012). Progesterone enhances vascular endothelial cell migration via activation of focal adhesion kinase. J Cell Mol Med 16, 296-305.